Curis, Inc.
Investor Relations Department
4 Maguire Road
Lexington, MA 02421
United States

Visit IR website
Sign-up for email alerts

NASDAQ: CRIS [1]		
Last Trade:		3.83
Trade Time:		4:00 PM ET May 24, 2013
Change:	0.05	(1.323%)
Day Range		3.74 - 3.87
52-Week Range		2.66 - 5.51
Volume		313,400
Market Cap. ($M)		308.461
Shares Out (M)		80.538

[1] The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.... (more)

Stock Performance

Press Releases [View all]

May 22, 2013
Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference

May 16, 2013
Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting

May 10, 2013
Curis Announces Approval of Erivedge(R) in Australia

Apr 30, 2013
Curis Reports First Quarter 2013 Financial Results

Apr 26, 2013
Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union

Events [View all]

May 29, 2013 8:40 AM ET
Deutsche Bank 38th Annual dbAccess Health Care Conference

Financials [View all]

First Quarter Financial Results

Mar 13, 2013
Annual Report (10-K)

Apr 16, 2013
Definitive Proxy Statement

May 9, 2013
Quarterly Report (10-Q)

Nov 6, 2012
Quarterly Report (10-Q)

Aug 9, 2012
Quarterly Report (10-Q)

NASDAQ OMX